SCHEMBL20161159

SCHEMBL20161159

FC(F)(F)c1n[nH]c(-c2nc(Cc3cncnc3)c3ncccn23)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21787227 0.85
SCHEMBL20141268 0.82 HIF1A (0.38)
SCHEMBL20161155 0.81 KCNK13 (0.32)
SCHEMBL20148889 0.80 AR (0.35)
SCHEMBL20161157 0.76 CACNA1B (0.32)
SCHEMBL20161109 0.75 PLA2G7 (0.31)
SCHEMBL20140383 0.74
SCHEMBL21564231 0.73 HDAC6 (0.30)
SCHEMBL21787428 0.73
SCHEMBL20148884 0.73 HIF1A (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
WO-2018111795-A2 USE OF SGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-06-21 WO disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed